Q4 2024 Earnings Call Transcript March 27, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

Shares of PDS Biotechnology Corporation (PDSB) drew investor attention on Thursday after the company reported ...

Analysts anticipate PDS Biotechnology to report an earnings per share (EPS) of $-0.30. Anticipation surrounds PDS ...

H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on PDS Biotechnology (PDSB) to $13 from $21 and keeps a Buy rating on ...

Good morning and welcome to PDS Biotech's 4th quarter in full year 2024 earnings conference call. Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's 2024 results and clinical ...

Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck CancerConference call and webcast today ...

PDS BIOTECHNOLOGY ($PDSB) posted quarterly earnings results on Thursday, March 27th. The company reported earnings of -$0.21 per share, beating estimates of -$0.28 by ...

PDS Biotechnology has a 12 month low of $1.13 and a 12 month high of $4.56. The firm has a market cap of $47.74 million, a price-to-earnings ratio of -1.08 and a beta of 1.68. Get PDS ...

Please go ahead, sir. Thank you, operator. Good morning, everyone. And welcome to PDS Biotech's 2024 results and clinical program update call. I am joined on the call today by the following ...

PRINCETON, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy ...

PRINCETON, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech” or the "Company”), a late-stage immunotherapy company focused on transforming how the ...